PLoS ONE (Jan 2014)

Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables.

  • Jose A Muñoz-Moreno,
  • Núria Pérez-Álvarez,
  • Amalia Muñoz-Murillo,
  • Anna Prats,
  • Maite Garolera,
  • M Àngels Jurado,
  • Carmina R Fumaz,
  • Eugènia Negredo,
  • Maria J Ferrer,
  • Bonaventura Clotet

DOI
https://doi.org/10.1371/journal.pone.0107625
Journal volume & issue
Vol. 9, no. 9
p. e107625

Abstract

Read online

ObjectiveWe used demographic and clinical data to design practical classification models for prediction of neurocognitive impairment (NCI) in people with HIV infection.MethodsThe study population comprised 331 HIV-infected patients with available demographic, clinical, and neurocognitive data collected using a comprehensive battery of neuropsychological tests. Classification and regression trees (CART) were developed to obtain detailed and reliable models to predict NCI. Following a practical clinical approach, NCI was considered the main variable for study outcomes, and analyses were performed separately in treatment-naïve and treatment-experienced patients.ResultsThe study sample comprised 52 treatment-naïve and 279 experienced patients. In the first group, the variables identified as better predictors of NCI were CD4 cell count and age (correct classification [CC]: 79.6%, 3 final nodes). In treatment-experienced patients, the variables most closely related to NCI were years of education, nadir CD4 cell count, central nervous system penetration-effectiveness score, age, employment status, and confounding comorbidities (CC: 82.1%, 7 final nodes). In patients with an undetectable viral load and no comorbidities, we obtained a fairly accurate model in which the main variables were nadir CD4 cell count, current CD4 cell count, time on current treatment, and past highest viral load (CC: 88%, 6 final nodes).ConclusionPractical classification models to predict NCI in HIV infection can be obtained using demographic and clinical variables. An approach based on CART analyses may facilitate screening for HIV-associated neurocognitive disorders and complement clinical information about risk and protective factors for NCI in HIV-infected patients.